Description
Composition- Sitagliptin 100 mg + Dapagliflozin 10 mg + Metformin 1000 mg
Mode of Action- Provides stronger triple-pathway glycemic control through DPP-4 inhibition, SGLT2 blockade and metformin-based insulin sensitization.
USPs- High-strength triple diabetes therapy; useful in difficult-to-control type 2 diabetes; broad glycemic management support.
Prescribing Specialties- Diabetologist, Internal Medicine
